Urologic Oncology: Seminars and Original Investigations This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Frailty as a predictor of complications after radical cystectomy: A prospective study of various preoperative assessments
In the United States in 2018, it is estimated 81,190 patients will be diagnosed with bladder cancer, and 17,240 patients will die due to the disease [1]. Both men and women are usually diagnosed at an advanced age, with an average age of 69 years for men and 71 years for women [2]. The 5-year cause-specific survival rate for those 60 to 65 years old is 84% and decreases to 60% in those 85 years and older [3]. While radical cystectomy is the gold standard treatment for muscle-invasive bladder cancer, this procedure carries significant morbidity, with reported 30-day complication rates ranging from 31.5% to 58% [4 –9] and ...
Source: Urologic Oncology: Seminars and Original Investigations - November 15, 2018 Category: Urology & Nephrology Authors: Madeleine L. Burg, Thomas G. Clifford, Soroush T. Bazargani, Michael Lin-Brande, Gus Miranda, Jie Cai, Anne K. Schuckman, Hooman Djaladat, Siamak Daneshmand Source Type: research

Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy
Open radical cystectomy (ORC) with pelvic lymph node dissection is the standard of care treatment for very high-risk non –muscle-invasive and muscle-invasive urothelial carcinoma of the bladder (UCB), providing durable local cancer control [1–3]. Even when performed by experienced surgeons, it is associated with significant morbidity including bleeding, pain associated with the incision and prolonged abdominal wal l retraction, as well as major fluid shifts [4]. Additionally, visibility of the surgical field can be difficult in the deep pelvic and retrovesical spaces [5–9]. (Source: Urologic Oncology: Seminars and Or...
Source: Urologic Oncology: Seminars and Original Investigations - November 14, 2018 Category: Urology & Nephrology Authors: Marco Moschini, Francesco Soria, Romain Mathieu, Evanguelos Xylinas, David D'Andrea, Wei Shen Tan, John D. Kelly, Giuseppe Simone, Gabriele Tuderti, Anoop Meraney, Suprita Krishna, Badrianath Konety, Stefania Zamboni, Philipp Baumeister, Agostino Mattei, Tags: Original Article Source Type: research

EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis
For locally advanced (including inguinal and pelvic lymph node metastatic disease) and distant metastatic penile squamous cell carcinoma (PSCC), multimodal treatments utilizing surgery, chemoradiotherapy and/or chemotherapy continue to be the most popular treatment regimen. Although several chemotherapy regimens combined with surgery have achieved encouraging short-term efficacies, long-term survival for those patients remains poor [1,2]. For patients with chemotherapy-failed experience, therapeutic options are even more limited. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - November 14, 2018 Category: Urology & Nephrology Authors: Kang-bo Huang, Ran-yi Liu, Qi-hua Peng, Zai-shang Li, Li-juan Jiang, Sheng-jie Guo, Qiang-hua Zhou, Ting-yu Liu, Chuang-zhong Deng, Kai Yao, Zi-ke Qin, Zhuo-wei Liu, Yong-hong Li, Hui Han, Fang-jian Zhou Tags: Original article Source Type: research

The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non –muscle-invasive bladder cancer: A preliminary results of randomized controlled trial
Immediate postoperative intravesical instillation of chemotherapy after transurethral resection of bladder tumor (TURBT) was shown by many investigators [1 –3] to reduce recurrence by eradication of any floating tumor cells. According to the European Association of Urology (EAU) guidelines, 1 postoperative intravesical instillation of chemotherapy after TURBT of presumably non–muscle-invasive bladder cancer (NMIBC) is recommended [4]. Evidence supp orting such practice was strengthened in 2004 by European Organization of Research and Treatment of Cancer (EORTC) meta-analysis incorporating all immediate postoperative ch...
Source: Urologic Oncology: Seminars and Original Investigations - November 14, 2018 Category: Urology & Nephrology Authors: Amr A. Elsawy, Ahmed M. El-Assmy, Mahmoud A. Bazeed, Bedeir Ali-El-Dein Tags: Original article Source Type: research

Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy
Urothelial carcinoma of the urinary bladder (UCB) is the seventh most common malignant tumor in men and the eleventh most common malignant tumor of both sexes [1]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Thomas Martini, Jakob Heinkele, Roman Mayr, Cleo-Aron Weis, Felix Wezel, Sarah Wahby, Markus Eckstein, Thomas Schn öller, Johannes Breyer, Ralph Wirtz, Manuel Ritter, Christian Bolenz, Philipp Erben Tags: Original article Source Type: research

Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer
Retroperitoneal lymph node dissection (RPLND) is an important component of the multimodal treatment which cures most patients diagnosed with testicular germ cell tumors. Considering the high cure rates achieved, research focus in recent years has been directed toward improving quality of life and decreasing long-term treatment related sequelae. Consequently, the role of RPLND has evolved over the past 3 decades in both low-stage and advanced testicular cancer.The use of RPLND in clinically stage I and low volume stage II disease may offer the advantages of treating retroperitoneal teratoma which is present in 15% to 20% of...
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Roy Mano, Renzo Di Natale, Joel Sheinfeld Tags: Seminars article Source Type: research

Diagnosis and management of the growing teratoma syndrome: A single-center experience and review of the literature
Testicular germ cell tumors are the most common solid neoplasms among young men with the highest incidence between the second and fourth decade [1]. Due to effective cisplatin-based chemotherapy and a risk-adapted interdisciplinary treatment approach, testicular cancer has a high cure rate even in advanced stages [1]. However, a small number of patients that receive cisplatin-based chemotherapy for metastatic nonseminomatous germ cell tumors (NSGCT) show growing metastatic masses despite normalized or decreasing tumor markers [2]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Pia Paffenholz, David Pfister, Vsevolod Matveev, Axel Heidenreich Tags: Original Article Source Type: research

Free-hand transperineal prostate biopsy provides acceptable cancer detection and minimizes risk of infection: evolving experience with a 10-sector template
In 2018, urologists in the United States will diagnose over 160,000 men with prostate cancer and will perform transrectal ultrasound-guided biopsies (TRUS-Bx) on many more [1,2]. TRUS-Bx was first popularized by Cooner in 1988 [3]. The technique was further refined by Stamey and colleagues who proposed the systematic sextant biopsy template in 1989 [4]. By the late 1990 ’s, clinicians recognized that a sextant biopsy missed up to 30% of prostate cancers giving rise to the current standard of 10 to 12 core TRUS-Bx [5,6]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Benjamin T. Ristau, Matthew Allaway, Demetri Cendo, John Hart, Jason Riley, Vasil Parousis, Peter C. Albertsen Tags: Original Article Source Type: research

The role of inguinal lymph node dissection in men with urethral squamous cell carcinoma
Primary urethral carcinoma (PUC) is a rare clinical entity and accounts for less than 1% of all genitourinary malignancies [1]. This has led to a relative paucity of data where management is largely informed by small, single-institution studies. Data from several national and international cohorts have been published [1 –4], but important questions remain with regard to the optimal management of this condition. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Ryan P. Werntz, Christopher B. Riedinger, Richard J. Fantus, Zachary L. Smith, Vignesh T. Packiam, Melanie A. Adamsky, Norm Smith, Gary D. Steinberg Tags: Original Article Source Type: research

Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy
Up to 30% of patients treated with radical prostatectomy (RP) for localized prostate cancer (PCa) will experience biochemical recurrence (BCR) within 10 years from surgery [1]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: David D'Andrea, Francesco Soria, Mohammad Abufaraj, Kilian Gust, Beat Foerster, Mihai D. Vartolomei, Shoji Kimura, Andrea Mari, Alberto Briganti, Mesut Remzi, Christian K. Seitz, Romain Mathieu, Pierre I. Karakiewicz, Shahrokh F. Shariat Source Type: research

Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Optimal treatment of locally advanced, N1 prostate cancer has not been determined. The experience from extended lymphadenectomy suggests that for a subgroup of patients with limited positive pelvic lymph nodes ( (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Jonathan Hayman, Knut H. Hole, Therese Seierstad, Jamie Perin, Theodore L. DeWeese, Phuoc T. Tran, Wolfgang Lilleby Source Type: research

Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients
Bladder cancer is one of the most common cancers in the United States and occurs in men more frequently than in women [1]. About 70% of bladder cancers are nonmuscle invasive, while the remaining patients have muscle invasive (MIBC) or metastatic tumors, with significantly reduced survival [2,3]. Smoking is recognized as the most important risk factor for bladder cancer, and smokers are 4 to 7 times more likely to develop bladder cancer than nonsmokers [4 –6]. Tobacco consumption may increase the risk of bladder cancer because of the accumulation of tobacco-derived chemicals in the urine, which in turn cause DNA damage i...
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Damiano Fantini, Roland Seiler, Joshua J. Meeks Tags: Seminars Article Source Type: research

Use of delayed intervention for small renal masses initially managed with active surveillance
A number of patients who elect active surveillance of their small renal masses ( ≤4 cm) subsequently pursue delayed intervention (DI). The indications, timing, and rates of DI have not been well determined prospectively. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Mohit Gupta, Ridwan Alam, Hiten D Patel, Alice Semerjian, Michael A. Gorin, Michael H. Johnson, Peter Chang, Andrew A. Wagner, James M. McKiernan, Mohamad E. Allaf, Phillip M. Pierorazio Tags: Clinical-Kidney cancer Source Type: research

Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy
This study aims to understand the role of MetS in influencing oncological outcomes at RP. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Alessandro Morlacco, Fabrizio Dal Moro, Laureano J. Rangel, Rachel E. Carlson, Phillip J. Schulte, Karnes R. Jeffrey Tags: Original article Source Type: research

Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database
Kidney cancer is the third most common genitourinary malignancy, with an estimated 65,340 new diagnoses and 14,970 deaths in 2018 [1]. The vast majority of kidney cancers are renal cell carcinoma (RCC), accounting for over 90% of renal parenchymal tumors [2]. RCC is associated with significant morbidity and mortality, and an especially poor prognosis when there is lymph node (LN) involvement. For example, numerous studies have identified both clinical and pathologic lymphadenopathy as independent adverse prognostic factors for cancer-specific survival (CSS) and all-cause mortality (ACM) [3]. (Source: Urologic Oncology: Sem...
Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Nicholas J. Farber, Zorimar Rivera-N úñez, Sinae Kim, Brian Shinder, Kushan Radadia, Joshua Sterling, Parth K. Modi, Sharad Goyal, Rahul Parikh, Tina M. Mayer, Robert E. Weiss, Isaac Y. Kim, Sammy E. Elsamra, Thomas L. Jang, Eric A. Singer Tags: Original Article Source Type: research